Zobrazeno 1 - 10
of 123
pro vyhledávání: '"E. Makarenko"'
Autor:
A. V. Suvorova, P. A. Losenkova, Yu. V. Medvedev, E. A. Malashenko, I. E. Makarenko, A. M. Poluyanov, I. E. Shohin
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 13, Iss 3, Pp 166-175 (2024)
Introduction. Deferasirox is a complexing drug and belongs to class II according to the biopharmaceutical classification system (BCS), has acidic properties and belongs to subclass “a” (acid). This class is characterized by high permeability and
Externí odkaz:
https://doaj.org/article/dbc1d4558e7042689e6d9613b3df9d1c
Autor:
A. N. Afanaseva, V. B. Saparova, I. E. Makarenko, T. A. Selmenskikh, D. V. Kurkin, A. L. Hohlov, R. V. Drai
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 13, Iss 1, Pp 247-255 (2024)
Introduction. Romiplostim is an analogue of the fusion protein peptide of thrombopoietin (TPO), which increases platelet count by binding and activating the human thrombopoietin receptor (TPO-R). It is used to treat thrombocytopenia associated with c
Externí odkaz:
https://doaj.org/article/b275653dfe8748d792b2e41f4c5157b3
Autor:
D. V. Kurkin, E. I. Morkovin, D. A. Bakulin, A. V. Zaborovsky, I. E. Makarenko, R. V. Drai, A. G. Solodovnikov, V. I. Petrov, K. N. Koryanova, N. A. Lycheva, S. A. Voskresensky, A. V. Strygin, Yu. A. Kolosov, Yu. V. Gorbunova, O. V. Ivanova
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 11, Iss 5, Pp 384-398 (2024)
The aim of the work was to conduct an analysis of the current state and current trends in the approval of drugs, as well as some aspects of the methodology for their development based on biological molecules and registration.Materials and methods. Th
Externí odkaz:
https://doaj.org/article/2dc8114950e748bbbd40243f3b14fe6b
Autor:
D. V. Kurkin, D. A. Bakulin, E. I. Morkovin, V. I. Petrov, A. V. Strygin, K. N. Koryanova, Yu. V. Gorbunova, Yu. A. Kolosov, O. V. Ivanova, E. V. Pavlova, M. A. Dzhavakhyan, A. V. Zaborovsky, V. B. Saparova, I. E. Makarenko, R. I. Drai, A. N. Chumachenko
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 11, Iss 4, Pp 347-380 (2024)
Modern approaches to the treatment of type 2 diabetes mellitus (T2DM) are aimed not only at glycemic control, but also at reducing cardiovascular risks. The increasing prevalence of the disease and the need for effective treatment options highlight t
Externí odkaz:
https://doaj.org/article/95f6d86f77b4438484e0b9ff432b4ee0
Autor:
D. V. Kurkin, E. I. Morkovin, D. A. Bakulin, Yu. V. Gorbunova, Yu. A. Kolosov, M. A. Dzhavakhyan, I. E. Makarenko, R. V. Drai, A. V. Zaborovsky, O. V. Shatalova, A. V. Strygin, V. I. Petrov, A. P. Pleten, A. A. Prokopov, T. Yu. Tatarenko-Kozmina
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 11, Iss 3, Pp 193-210 (2023)
The aim of the work is to conduct a review of medications approved by the FDA in 2022.Materials and methods. In searching for the materials to write this review article, bibliographic databases including PubMed, Google Scholar and e-library.ru were u
Externí odkaz:
https://doaj.org/article/8583ca5a7d4043de9ab1b0dd5ccb0858
Autor:
A. N. Arevefa, A. R. Dorotenko, S. M. Noskov, I. E. Makarenko, R. V. Drai, T. N. Komarov, O. A. Archakova, N. S. Bagaeva, I. E. Shokhin
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 12, Iss 3, Pp 218-227 (2023)
Introduction. Citicoline is an endogenous nucleoside consisting of cytidine and choline linked by a diphosphate bridge that is involved in the synthesis of membrane phospholipids. Drugs containing citicoline have neuroprotective and neurometabolic ef
Externí odkaz:
https://doaj.org/article/ccf7fc38cfed460b835470037a54f63e
Autor:
A. V. Babina, R. V. Drai, V. B. Saparova, A. N. Afanasyeva, P. G. Zaikin, V. I. Shmurak, T. E. Eltysheva, I. E. Makarenko
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 12, Iss 2, Pp 124-134 (2023)
Introduction. Currently, biosimilars have found quite widespread use in the treatment of a number of chronic and life-threatening diseases. Thanks to them, there is a significant decrease of the economic pressure of biological drugs on the health car
Externí odkaz:
https://doaj.org/article/786a8dd4fc784d75aae394661378ffa3
Autor:
D. V. Kurkin, D. A. Bakulin, E. I. Morkovin, A. V. Strygin, Yu. V. Gorbunova, E. V. Volotova, I. E. Makarenko, V. B. Saparova, R. V. Drai, V. I. Petrov
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 11, Iss 1, Pp 19-47 (2023)
Modern requirements for the treatment of type 2 diabetes mellitus (DM2) include not only achieving a glycemic control, but also reducing the risk of developing cardiovascular complications. Dipeptidyl peptidase 4 (DPP-4) inhibitors are inferior in th
Externí odkaz:
https://doaj.org/article/f0fe50a3b67f4dd0bc0505b700df9935
Publikováno v:
Регуляторные исследования и экспертиза лекарственных средств, Vol 13, Iss 1, Pp 77-88 (2023)
Russian and international regulatory documents require that analytical procedures for establishing bioequivalence and comparability of quality attributes of biotechnological (biological) products, carrying out batch release of medicinal products, and
Externí odkaz:
https://doaj.org/article/d6fd7359d73b4bbc8d3817c970259007
Autor:
A. N. Afanasyeva, V. B. Saparova, D. D. Karal-Ogly, E. I. Mukhametzyanova, D. V. Kurkin, A. V. Kalatanova, I. E. Makarenko, A. L. Khokhlov, I. A. Lugovik
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 10, Iss 4, Pp 354-370 (2022)
Idiopathic thrombocytopenic purpura is a chronic autoimmune hematological disease caused by an increased destruction of platelets and associated thrombocytopenia, for the treatment of which the imported drug romiplostim is used. Сreation of the drug
Externí odkaz:
https://doaj.org/article/a5cc49ccab96497c88981a4904fcda8c